Atara Biotherapeutics Inc (ATRA NASDAQ) stock market data APIs
$11.6469
-0.11(-0.9%)
as of September 17, 2025
Try our APIs with
free plan!
Atara Biotherapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Prev. Close
11.6469
Open
11.538
High
11.7774
Low
11.4891
52 wk Range
5.005-18.705
Market Cap
81 397 K
P/E Ratio
16.0972
Shares Outstanding
7 023 K
Revenue
189 M
EPS
0.19
Beta
0.223
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Atara Biotherapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Atara Biotherapeutics Inc data using free add-ons & libraries
Get Atara Biotherapeutics Inc Fundamental Data
Atara Biotherapeutics Inc Fundamental data includes:
- Net Revenue: 189 M
- EBITDA: 23 976 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-11
- EPS/Forecast: -0.27
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Atara Biotherapeutics Inc News
New
Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed
This article summarizes the most significant insider buys and sells reported for US stocks on Tuesday, August 19, 2025. Top Insider Buys: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) saw Director James...
Atara biotherapeutics (ATRA) director Huang buys $670k in stock
Director James Huang of Atara Biotherapeutics, Inc. (NASDAQ: NASDAQ:ATRA), a company with a market capitalization of $78.83 million, reported purchasing 55,000 shares of common stock on August 15, 202...
Mizuho lowers Atara Biotherapeutics stock price target on delayed tab-cel launch
Investing.com - Mizuho has lowered its price target on Atara Biotherapeutics (NASDAQ:ATRA) to $16.00 from $18.00 while maintaining an Outperform rating on the stock. The company, currently trading at ...
Pinnacle Financial Partners Enters Oversold Territory
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
